Carini, C., Hunter, E., Scottish Early Rheumatoid Arthritis Inception cohort, , Ramadass, A. S., Green, J., Akoulitchev, A., McInnes, I. B. and Goodyear, C. S. (2018) Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis. Journal of Translational Medicine, 16(1), 18. (doi: 10.1186/s12967-018-1387-9) (PMID:29378619) (PMCID:PMC5789697)
|
Text
157074.pdf - Published Version Available under License Creative Commons Attribution. 1MB |
Abstract
Background: There is a pressing need in rheumatoid arthritis (RA) to identify patients who will not respond to first-line disease-modifying anti-rheumatic drugs (DMARD). We explored whether differences in genomic architecture represented by a chromosome conformation signature (CCS) in blood taken from early RA patients before methotrexate (MTX) treatment could assist in identifying non-response to DMARD and, whether there is an association between such a signature and RA specific expression quantitative trait loci (eQTL). Methods: We looked for the presence of a CCS in blood from early RA patients commencing MTX using chromosome conformation capture by EpiSwitch™. Using blood samples from MTX responders, non-responders and healthy controls, a custom designed biomarker discovery array was refined to a 5-marker CCS that could discriminate between responders and non-responders to MTX. We cross-validated the predictive power of the CCS by generating 150 randomized groups of 59 early RA patients (30 responders and 29 non-responders) before MTX treatment. The CCS was validated using a blinded, independent cohort of 19 early RA patients (9 responders and 10 non-responders). Last, the loci of the CCS markers were mapped to RA-specific eQTL. Results: We identified a 5-marker CCS that could identify, at baseline, responders and non-responders to MTX. The CCS consisted of binary chromosome conformations in the genomic regions of IFNAR1, IL-21R, IL-23, CXCL13 and IL-17A. When tested on a cohort of 59 RA patients, the CCS provided a negative predictive value of 90.0% for MTX response. When tested on a blinded independent validation cohort of 19 early RA patients, the signature demonstrated a true negative response rate of 86 and a 90% sensitivity for detection of non-responders to MTX. Only conformations in responders mapped to RA-specific eQTL. Conclusions: Here we demonstrate that detection of a CCS in blood in early RA is able to predict inadequate response to MTX with a high degree of accuracy. Our results provide a proof of principle that a priori stratification of response to MTX is possible, offering a mechanism to provide alternative treatments for non-responders to MTX earlier in the course of the disease.
Item Type: | Articles |
---|---|
Keywords: | Chromatin conformation signatures (CCS), DMARDs (synthetic), early rheumatoid arthritis, expression quantitative trait loci (eQTL), methotrexate, methotrexate (MTX), precision medicine drug response biomarkers, rheumatoid arthritis. |
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | McInnes, Professor Iain and Goodyear, Professor Carl and Gilmour, Miss Ashley |
Authors: | Carini, C., Hunter, E., Scottish Early Rheumatoid Arthritis Inception cohort, , Ramadass, A. S., Green, J., Akoulitchev, A., McInnes, I. B., and Goodyear, C. S. |
College/School: | College of Medical Veterinary and Life Sciences > School of Infection & Immunity |
Journal Name: | Journal of Translational Medicine |
Publisher: | BioMed Central |
ISSN: | 1479-5876 |
ISSN (Online): | 1479-5876 |
Copyright Holders: | Copyright © 2018 The Authors |
First Published: | First published in Journal of Translational Medicine 16(1):18 |
Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record